RAMSEY, N.J. and BOCA RATON, Fla., April 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA" or the "Company"), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection. The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti- pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti- pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti- pneumococcal immune globulin. This patent will enable ADMA to protect its proprietary rights and at the same time attract collaborators interested in the development, marketing and commercialization of a much needed therapeutic for the treatment and prevention of infection in immune compromised, immunodeficient, and elderly patients who are poorly responsive to available S. pneumonia vaccines.